Literature DB >> 24018211

Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

L Puig1, J M Carrascosa, G Carretero, P de la Cueva, R F Lafuente-Urrez, I Belinchón, M Sánchez-Regaña, M García-Bustínduy, M Ribera, M Alsina, C Ferrándiz, E Fonseca, V García-Patos, E Herrera, J L López-Estebaranz, S E Marrón, J C Moreno, J Notario, R Rivera, C Rodriguez-Cerdeira, A Romero, R Ruiz-Villaverde, R Taberner, D Vidal.   

Abstract

Biologic therapy is a well-established strategy for managing moderate and severe psoriasis. Nevertheless, the high cost of such therapy, the relatively short span of clinical experience with biologics, and the abundance of literature now available on these agents have made evidence-based and consensus-based clinical guidelines necessary. The ideal goal of psoriasis treatment is to achieve complete or nearly complete clearing of lesions and to maintain it over time. Failing that ideal, the goal would be to reduce involvement to localized lesions that can be controlled with topical therapy. Although current evidence allows us to directly or indirectly compare the efficacy or risk of primary or secondary failure of available biologics based on objective outcomes, clinical trial findings cannot be directly translated to routine practice. As a result, the prescribing physician must tailor the treatment regimen to the individual patient. This update of the clinical practice guidelines issued by the Spanish Academy of Dermatology and Venereology (AEDV) on biologic therapy for psoriasis incorporates information from the most recent publications on this topic.
Copyright © 2013 Elsevier España, S.L. and AEDV. All rights reserved.

Entities:  

Keywords:  Adalimumab; Biologic agents; Biologic therapy; Biológicos; Clinical practice guidelines; Etanercept; Guía; Infliximab; Psoriasis; Terapia biológica; Tratamiento; Treatment; Ustekinumab

Mesh:

Substances:

Year:  2013        PMID: 24018211     DOI: 10.1016/j.adengl.2013.04.013

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  11 in total

1.  Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.

Authors:  Selma Atalay; Lara S van der Schoot; Laura Vandermaesen; Lieke J van Vugt; Mascha Eilander; Juul M P A van den Reek; Elke M G J de Jong
Journal:  Acta Derm Venereol       Date:  2021-05-25       Impact factor: 3.875

2.  Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study.

Authors:  Nikolai Loft; Alexander Egeberg; Mads Kirchheiner Rasmussen; Lars Erik Bryld; Christoffer V Nissen; Tomas Norman Dam; Kawa Khaled Ajgeiy; Lars Iversen; Lone Skov
Journal:  Acta Derm Venereol       Date:  2021-01-04       Impact factor: 3.875

3.  Predictors of biologic treatment of psoriasis: a non-interventional study.

Authors:  Luis Puig; Tao Fan; Qian Ding; Nancy E Smith
Journal:  Clinicoecon Outcomes Res       Date:  2014-02-17

4.  Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).

Authors:  S K Mahil; N Wilson; N Dand; N J Reynolds; C E M Griffiths; R Emsley; A Marsden; I Evans; R B Warren; D Stocken; J N Barker; A D Burden; C H Smith
Journal:  Br J Dermatol       Date:  2019-09-10       Impact factor: 9.302

5.  Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.

Authors:  Erin Johansson; Mercedes Nuñez; Axel Svedbom; Tatiana Dilla; Susanne Hartz
Journal:  Clinicoecon Outcomes Res       Date:  2018-11-12

6.  Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review.

Authors:  Lluís Puig; Lourdes Rodríguez Fernández-Freire; Ramón Burgos-Pol; Ismael Gomez; Carmen Peral; Susana Gomez; Francisco José Rebollo Laserna
Journal:  Dermatol Ther (Heidelb)       Date:  2019-05-06

Review 7.  Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability.

Authors:  Christina Rogalski
Journal:  Psoriasis (Auckl)       Date:  2015-06-08

8.  Considerable variation among Iranian dermatologists in the knowledge and attitudes regarding the use of biologic agents to manage psoriasis.

Authors:  Mina Almasi-Nasrabadi; Reza M Robati; Omid Zargari; Mohammad Shahidi-Dadras
Journal:  Int J Womens Dermatol       Date:  2019-11-07

9.  Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World.

Authors:  Cristina Galache Osuna; Sebastián Reyes García; Jimena Carrero Martín; Virginia García Jiménez; Francisco Vázquez López; Jorge Santos-Juanes
Journal:  Life (Basel)       Date:  2021-12-07

10.  Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document.

Authors:  Isabel Belinchón Romero; Esteban Dauden; Carlos Ferrándiz Foraster; Álvaro González-Cantero; Jose Manuel Carrascosa Carrillo
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.